Non-24-hour sleep–wake disorder

In blind people

It has been estimated that non-24 occurs in more than half of all people who are totally blind. The disorder can occur at any age, from birth onwards. It generally follows shortly after loss or removal of a person's eyes, as the photosensitive ganglion cells in the retina are also removed.

Without light to the retina, the suprachiasmatic nucleus (SCN), located in the hypothalamus, is not cued each day to synchronize the circadian rhythm to the 24-hour social day, resulting in non-24 for many totally blind individuals. Non-24 is rare among visually impaired patients who retain at least some light perception. Researchers have found that even minimal light exposure at night can affect the body clock.

Symptoms

People with this disorder might find it difficult to follow a regular clock scheme, as their biological clock can shift so much that they are sleepy during the day and experience insomnia during night. Another common diagnostic feature is the cyclical nature of non-24: people will experience certain periods, whether they be weeks or months, of sleeping during the day (symptomatic periods) that alternate with periods of sleeping during normal nighttime hours (asymptomatic periods).

Symptoms reported by patients forced into a 24-hour schedule are similar to those of sleep deprivation and can include:

• Apraxia, including ideational apraxia, ideomotor apraxia, kinetic apraxia, limb apraxia, verbal apraxia
• Cognitive dysfunction
• Difficulties concentrating
• Confusion
• Depressed mood
• Diarrhea
• Extreme nausea
• Extreme fatigue
• Hair loss
• Headaches
• Impaired balance
• Photosensitivity
• Joint pain
• Loss of muscle coordination (ataxia)
• Menstrual irregularities
• Muscle pain
• Suicidal thoughts
• Weight gain
• Hallucinations

Causes

The possible causes of non-24-hour sleep-wake disorder are 2-fold: (1), extrinsic: isolation from daily light cycles (such as working in an environment completely devoid of natural lighting); and (2), intrinsic: where some condition, such as blindness or malfunctioning biochemical response to light in the subject, prevent normal levels of light-activated melatonin release. Melatonin is responsible for sleep regulation, and its release is controlled by the amount of light entering the eyes.

Sighted

Sighted people with non-24 appear to be more rare than blind people with the disorder, and the etiology of their circadian disorder is less well understood. At least one case of a sighted person developing non-24 was preceded by head injury; another patient diagnosed with the disorder was later found to have a "large pituitary adenoma that involved the optic chiasma". Thus the problem appears to be neurological. Specifically, it is thought to involve abnormal functioning of the suprachiasmatic nucleus (SCN) in the hypothalamus. Several other cases have been preceded by chronotherapy, a prescribed treatment for delayed sleep phase disorder. "Studies in animals suggest that a hypernyctohemeral syndrome could occur as a physiologic aftereffect of lengthening the sleep–wake cycle with chronotherapy". According to the American Academy of Sleep Medicine (AASM), "patients with free-running (FRD) rhythms are thought to reflect a failure of entrainment".

There have been several experimental studies of sighted people with the disorder. McArthur et al. reported treating a sighted patient who "appeared to be subsensitive to bright light". In other words, the brain (or the retina) does not react normally to light (people with the disorder may or may not, however, be unusually subjectively sensitive to light; one study found that they were more sensitive than the control group). In 2002 Uchiyama et al. examined five sighted non-24 patients who showed, during the study, a sleep–wake cycle averaging 25.12 hours. That is appreciably longer than the 24.02-hour average shown by the control subjects in that study, which was near the average innate cycle for healthy adults of all ages: the 24.18 hours found by Charles Czeisler. The literature usually refers to a "one- to two-hour" delay per 24-hour day (i.e. a 25- to 26-hour cycle).

Uchiyama et al. had earlier determined that sighted non-24 patients' minimum core body temperature occurs much earlier in the sleep episode than the normal two hours before awakening. They suggest that the long interval between the temperature trough and awakening makes illumination upon awakening virtually ineffective, as per the phase response curve (PRC) for light.

In their clinical review in 2007, Okawa and Uchiyama reported that people with non-24 have a mean habitual sleep duration of nine to ten hours and that their circadian periods average 24.8 hours.

Blind

As stated above, the majority of patients with non-24 are totally blind. The failure of entrainment is explained by the loss of photic input to the circadian clock. Non-24 is rare among visually impaired patients who retain at least some light perception; even minimal light exposure can synchronize the body clock. A few cases have been described in which patients are subjectively blind, but are normally entrained and have an intact response to the suppressing effects of light on melatonin secretion, indicating preserved neural pathways between the retina and hypothalamus.

Circadian rhythm

All living animals have an internal clock, the circadian rhythm, which is close to 24 hours' duration. For humans, the average duration is 24 hours and 20 minutes, and individually some people have more or less than 24 hours. Everyday exposure to the morning light resets the circadian rhythm to 24 hours, so that there is no drifting.

However, people with non-24 have a circadian rhythm significantly longer (or, rarely, shorter) than 24 hours. This makes it difficult to reset to 24 hours daily, just like it is difficult for people with a rhythm close to 24 hours to try to reset to 25 hours daily. The majority of people with non-24 are totally blind, and the failure of entrainment is explained by an absence of light (photic) input to reset the circadian clock. Their brains may have normal circadian clocks that do not receive input from the eyes about environmental light levels, as the clocks require a functioning retina, optic nerve, and visual processing center. This makes the sleep pattern variable from one day to the next, with different wake-up time and bedtime every day.

People with a circadian rhythm that is quite near to 24 hours may be able to sleep on a conventional, socially acceptable schedule, that is, at night. Others, with a "daily" cycle upwards of 25 hours or more, may need to adopt a sleep pattern that is congruent with their free-running circadian clock: by daily shifts in their sleep times, which often results in satisfactory sleep but with negative social and occupational consequences.

The disorder also occurs in sighted people for reasons that are not well understood. Their circadian rhythms are not normal, often running to more than 25 hours. Their visual systems may function normally but their brains are incapable of making the large adjustment to a 24-hour schedule.

Though often referred to as non-24, for example by the FDA, the disorder is also known as: non-24-hour sleep–wake syndrome or disorder, circadian rhythm sleep disorder—free-running type or nonentrained type, non-24-hour circadian rhythm disorder. or just N24 for short in everyday speech.

The disorder is an invisible disability that can be "extremely debilitating in that it is incompatible with most social and professional obligations".

Mechanisms

The internal circadian clock, located in the hypothalamus of the brain, generates a signal that normally is slightly longer (occasionally shorter) than 24 hours, on average 24 hours and 11 minutes. This slight deviation is, in almost everyone, corrected by exposure to environmental time cues, especially the light–dark cycle, which reset the clock and synchronize (entrain) it to the 24-hour day. Morning light exposure resets the clock earlier, and evening exposure resets it later, thereby bracketing the rhythm to an average 24-hour period. If people who do not have non-24-hour sleep-wake disorder are deprived of external time cues (living in a cave or artificial time-isolated environment with no light), their circadian rhythms will "free-run" with a cycle of a little more (occasionally less) than 24 hours, expressing the intrinsic period of each individual's circadian clock. The circadian rhythms of individuals with non-24 can resemble those of experimental subjects living in a time-isolated environment even though they are living in normal society.

The circadian clock modulates many physiological rhythms. The most easily observed of these is the propensity for sleep and wake; thus, people with non-24 experience symptoms of insomnia and daytime sleepiness (similar to "jet lag") when their endogenous circadian rhythms drift out of synchrony with the social/solar 24-hour day, but they conform to a conventional schedule. Eventually, their circadian rhythms will drift back into normal alignment, when symptoms temporarily resolve. Thus the overall pattern involves periodic symptoms on a weekly or monthly basis, depending on the length of the internal circadian cycle. For example, an individual with a circadian period of 24.5 hours would drift 30 minutes later each day and would be maximally misaligned every 48 days. If patients set their own schedule for sleep and wake, aligned to their endogenous non-24 period (as is the case for most sighted patients with this disorder), symptoms of insomnia and wake-time sleepiness are much reduced. However, such a schedule is incompatible with most occupations and social relationships.

The AASM suggests that non-24 might be different disorders in sighted and blind people, with different internal and external contributing factors—as these can affect treatment response, different treatments could be needed.This assumes that multiple treatments exist. Future studies should therefore try to identify and assess these factors.

Diagnosis

This disorder can have symptomatic periods, where "the time of high sleep propensity gradually shifts, such that patients experience daytime hypersomnolence and nighttime insomnia".

In sighted people, the diagnosis is typically made based on a history of persistently delayed sleep onset that follows a non-24-hour pattern. Hayakawa et al. (2005) reported on the basis of 57 cases of sighted patients that the average day length was 24.9 ± 0.4 hours (with the range of 24.4–26.5).

Medical classification

International Classification of Sleep Disorders (ICSD)

Since 2005, the disorder has been recognized by name in the U.S. National Center for Health Statistics and the U.S. Centers for Medicare and Medicaid Services in their adaptation and extension of the WHO's International Statistical Classification of Diseases and Related Health Problems (ICD):

• ICD-9-CM: Circadian rhythm sleep disorder, free-running type; code 327.34 became effective in October 2005. Prior to the introduction of this code, the nonspecific code 307.45, Circadian rhythm sleep disorder of non-organic origin, was available, and as of 2014 remains the code recommended by the DSM-5.
• ICD-10-CM: Circadian rhythm sleep disorder, free running type; code G47.24 was due to take effect October 1, 2014.

Since 2013, the disorder has been recognized by the American Psychiatric Association:

• DSM-5, 2013: Circadian rhythm sleep–wake disorders, Non-24-hour sleep–wake type; ICD-9-CM code 307.45 is recommended (no acknowledgement of 327.34 is made), and ICD-10-CM code G47.24 is recommended when it goes into effect.

Treatment

Tasimelteon

The Food and Drug Administration (FDA) approved in January 2014 the melatonin agonist tasimelteon for the treatment of non-24 for blind people. This is the first FDA-approved drug for any circadian rhythm sleep disorder, since melatonin is unregulated. In the largest treatment study with non-24 patients, it was demonstrated that tasimelteon safely and effectively treated totally blind patients: entrainment occurred in 20% (8 of 40) of patients receiving the drug compared with 3% (1 of 38) receiving placebo. In a separate meta-analysis, melatonin supplementation achieved a 67% (12 of 18) entrainment rate. Studies directly comparing tasimelteon and melatonin have yet to be performed. Study authors noted that the lower rates of entrainment with tasimelteon may have been due to short duration of treatment.

Melatonin, light therapy and dark therapy

Melatonin administration 1 hour before bedtime is considered another treatment for non-24. However, it is important to note that melatonin may only treat the inability to sleep and may not help to improve the daytime sleepiness.

Light therapy, which involves a bright light exposure of thousands of lux of white light or about 400 lux of blue light on awakening to counteract the tendency for circadian rhythms to delay (similar to treatment for delayed sleep phase disorder and seasonal affective disorder), is not currently recommended until more studies appear, although it has been found to be effective in some cases. This can be combined with dark therapy (or scototherapy), which involves filtering blue light (using software, screen filters or (amber-color) glasses) and preferring red-colored lights with a low amount of lux in the few hours before bedtime to avoid melatonin suppression.

Both melatonin administration and light therapy work by shifting circadian rhythms according to a phase response curve (PRC), with the melatonin PRC being essentially the inverse of the light PRC. Furthermore, light can suppress melatonin secretion.

In addition to natural fluctuations within the circadian rhythm, seasonal changes including temperature, hours of daylight, light intensity and diet are likely to affect the efficacy of melatonin and light therapies since these exogenous zeitgebers would compete for hormonal homeostasis. Further to this, there are unforeseen disruptions to contend with even when a stabilized cycle is achieved, such as travel, exercise, stress, alcohol, or even the use of light-emitting technology close to a subjective evening/night.

Prevalence

There are an estimated 140,000 people with non-24—both sighted and blind—in the European Union, a total prevalence of approximately 3 per 10,000, or 0.03%. It is unknown how many individuals with this disorder do not seek medical attention, so incidence may be higher. The European portal for rare diseases, Orphanet, lists non-24 as a rare disease by their definition: fewer than 1 affected person for every 2000 population. The US National Organization for Rare Disorders (NORD) lists non-24 as a rare disease by its definition.

Blind

While both sighted and blind people are diagnosed with non-24, the disorder is believed to affect up to 70% of totally blind individuals. 10% have no light perception at all. Of that group, it is estimated that approximately half to three-quarters, or 65,000 to 95,000 Americans, have non-24.

History

In the 1980s and 1990s, several trials of melatonin administration to totally blind individuals without light perception produced improvement in sleep patterns, but it was unclear at that time if the benefits were due to entrainment from light cues. The ability of melatonin administration to entrain free-running rhythms was first demonstrated by Redman, et al. in 1983 in rats who were maintained in a time-free environment. Then, using endogenous melatonin as a marker for circadian rhythms, several research groups showed that appropriately timed melatonin administration could entrain free-running rhythms in the totally blind: they found that 6 out of 7 patients treated with 10 mg melatonin at bedtime were normally entrained, and when the dose was gradually reduced to 0.5 mg in three of the subjects, entrainment persisted. Subsequently, it was observed that treatment initiated with the 0.5 mg dose could produce entrainment on some patients. Interestingly, one subject who failed to entrain at a higher dose was successfully entrained at a lower dose. A low dose produces melatonin blood levels that are similar to the concentrations naturally produced by nightly pineal secretion.

There has been a constant growth in the field of melatonin and melatonin receptor agonists since the 1980s. In 2005, ramelteon (trade name Rozerem) was the first melatonin agonist to be approved in the United States (US), indicated for insomnia treatment in adults. Melatonin in the form of prolonged release (trade name Circadin) was approved in 2007 in Europe (EU) for use as a short-term treatment, in patients 55 years and older, for primary insomnia. Tasimelteon (trade name Hetlioz) received FDA approval in January 2014 for blind persons diagnosed with non-24. TIK-301 (Tikvah Therapeutics, Atlanta, USA) has been in phase II clinical trial in the United States since 2002 and the FDA granted it orphan drug designation in May 2004, for use as a treatment for circadian rhythm sleep disorder in blind individuals without light perception as well as individuals with tardive dyskinesia.

The first report and description of a case of non-24, a man living on 26-hour days, who happened to be sighted, was "A man with too long a day" by Ann L. Eliott et al. in November 1970. The related and more common delayed sleep phase disorder was not described until 1981.

The first detailed study of non-24 in a blind subject was by Miles Le and his colleagues in 1977. The researchers reported on a 28-year-old male who had a 24.9-hour rhythm in sleep, plasma cortisol, and other parameters. Even while adhering to a typical 24-hour schedule for bedtime, rise time, work, and meals, the man's body rhythms continued to shift.

Research

Not all totally blind individuals have free-running rhythms, and those that do often show relative coordination as their endogenous rhythms approximate normal timing. It has been suggested that there are non-photic time cues that are important for maintaining entrainment, but these cues are yet to be characterized.

Very preliminary research on light sensitivity suggest that not only insensitivity but also circadian hypersensitivity to light might be at play for patients with a delayed sleep phase disorder.

Society

NASA explored the potential impact on circadian rhythm and possible development of a sleep–wake disorder by human astronauts who would go on a mission to Mars, by assessing mission personnel who worked remotely on the Phoenix Mars Lander project and were asked to follow a Mars day of 24.65 hours for 78 days.

Notes

References

References

1. Fadden, James S. P.. (May 12, 2015). "What You Need to Know About Non-24".
2. "Non-24-Hour Sleep-Wake Disorder".
3. (15 October 2015). "Clinical Practice Guideline for the Treatment of Intrinsic Circadian Rhythm Sleep–Wake Disorders: Advanced Sleep–Wake Phase Disorder (ASWPD), Delayed Sleep–Wake Phase Disorder (DSWPD), Non-24-Hour Sleep–Wake Rhythm Disorder (N24SWD), and Irregular Sleep–Wake Rhythm Disorder (ISWRD). An Update for 2015: An American Academy of Sleep Medicine Clinical Practice Guideline.". Journal of Clinical Sleep Medicine.
4. (November 2007). "Practice parameters for the clinical evaluation and treatment of circadian rhythm sleep disorders. An American Academy of Sleep Medicine report.". Sleep.
5. (December 2007). "Circadian rhythm sleep disorders: characteristics and entrainment pathology in delayed sleep phase and non-24-h sleep–wake syndrome". Sleep Med Rev.
6. American Academy of Sleep Medicine. (2001). "The International Classification of Sleep Disorders, Revised (ICSD-R)". American Sleep Disorders Association.
7. (2009). "Non-24-Hour Sleep–wake Syndrome in Sighted and Blind Patients". Sleep Med Clin.
8. (August 2000). "Sensitivity of the human circadian pacemaker to nocturnal light: melatonin phase resetting and suppression". J. Physiol..
9. (2007). "Visual impairment and circadian rhythm disorders". Dialogues Clin Neurosci.
10. (2007). "Circadian rhythm sleep disorders: part II, advanced sleep phase disorder, delayed sleep phase disorder, free-running disorder, and irregular sleep-wake rhythm. An American Academy of Sleep Medicine review". Sleep.
11. Peters, Brandon. "Can Sleep Deprivation Cause Hallucinations". About.com.
12. (December 2021). "Disturbance of the Circadian System in Shift Work and Its Health Impact". Journal of Biological Rhythms.
13. (August 2018). "Suppression of Melatonin Secretion in Totally Visually Blind People by Ocular Exposure to White Light: Clinical Characteristics". Ophthalmology.
14. (2007-04-04). "Melatonin the "light of night" in human biology and adolescent idiopathic scoliosis". Scoliosis.
15. El-Ad, Baruch. (April 9, 2009). "Circadian rhythm sleep disorder: free-running type". MedLink Neurology.
16. (June 2003). "Non-24-hour sleep–wake syndrome following a car accident". Neurology.
17. Stores G. (2003). "Misdiagnosing sleep disorders as primary psychiatric conditions". Advances in Psychiatric Treatment.
18. Moegenthaler, TI. (November 2007). "Standards of Practice Committee of the AASM. Practice Parameters for the Clinical Evaluation and Treatment of Circadian Rhythm Sleep Disorder". Sleep.
19. (1996). "Non-24-hour sleep–wake syndrome in a sighted man: circadian rhythm studies and efficacy of melatonin treatment". Sleep.
20. (2002). "Larger phase angle between sleep propensity and melatonin rhythms in sighted humans with non-24-hour sleep–wake syndrome". Sleep.
21. (July 15, 1999). "Human Biological Clock Set Back an Hour". Harvard University Gazette.
22. (2000). "Altered phase relation between sleep timing and core body temperature rhythm in delayed sleep phase disorder and non-24-hour sleep–wake syndrome in humans". Neuroscience Letters.
23. Klerman EB, Shanahan TL, Brotman DJ, Rimmer DW, Emens JS, Rizzo JF, 3rd. (2002). "Photic resetting of the human circadian pacemaker in the absence of conscious vision". J Biol Rhythms.
24. (December 2016). "Circadian rhythm and sleep disruption: Causes, metabolic consequences, and countermeasures". Endocrine Reviews.
25. (14 November 2013). "Tasimelteon". FDA.
26. (April 2019}} hypernychthemeral syndrome, hypernychthemeral sleep-wake cycle disturbance,{{cite journal). "Long-Term Ambulatory Temperature Monitoring in a Subject with a Hypernychthemeral Sleep-Wake Cycle Disturbance". Sleep.
27. (August 2019). "Non-24-hour Sleep-Wake Rhythm Disorder". Neurologic Clinics.
28. (10 December 1992). "Hypernyctohemeral syndrome after chronotherapy for delayed sleep phase syndrome". New England Journal of Medicine.
29. "Non-24-Hour Sleep-Wake Disorder".
30. Abbott SM. (2019). "Non-24-hour Sleep-Wake Rhythm Disorder.". Neurol Clin.
31. (2005). "Clinical analyses of sighted patients with non-24-hour sleep–wake syndrome: a study of 57 consecutively diagnosed cases". Sleep.
32. The American Academy of Sleep Medicine, the European Sleep Research Society, the Japanese Society of Sleep Research, and the Latin American Sleep Society, ''International Classification of Sleep Disorders,'' 3rd Ed. (Darien, Illinois: 2014).
33. American Academy of Sleep Medicine, European Academy of Sleep Medicine, European Sleep Research Society, the Japanese Society of Sleep Research, and the Latin American Sleep Society, ''The International Classification of Sleep Disorders: Diagnostic and Coding Manual'' (Westchester, Ill., 2005).
34. American Sleep Disorders Association, European Sleep Research Society, the Japanese Society of Sleep Research and the Latin American Sleep Society, ''The International Classification of Sleep Disorders, Revised: Diagnostic and Coding Manual'' (Rochester, Minn.: 1997).
35. (1979). "Diagnostic classification of sleep and arousal disorders. 1979 first edition. Association of Sleep Disorders Centers and the Association for the Psychophysiological Study of Sleep.". Sleep.
36. DSM-5 (2013), p. 390: "For ICD-9-CM, code 307.45 for all subtypes. For ICD-10-CM, code is based on subtype."
37. (1998). "Periodic fatigue symptoms due to desynchronization in a patient with non-24-h sleep–wake syndrome". Psychiatry and Clinical Neurosciences.
38. (1989). "Entrainment of a free-running human with bright light?". Chronobiol. Int..
39. "New Drugs Online Report for tasimelteon". UK Medicines Information, National Health Service.
40. Orphanet. (April 2006). "Hypernychthemeral syndrome". Inserm: Institut national de la santé et de la recherche médicale.
41. "Non-24-Hour Sleep-Wake Disorder - Circadian Rhythm Disorder".
42. (January 1995). "Suppression of melatonin secretion in some blind patients by exposure to bright light". N. Engl. J. Med..
43. (July 1992). "Circadian rhythm abnormalities in totally blind people: incidence and clinical significance". J. Clin. Endocrinol. Metab..
44. (1988). "Synchronisation of a disturbed sleep–wake cycle in a blind man by melatonin treatment". Lancet.
45. (1990). "Melatonin stabilises sleep onset time in a blind man without entrainment of cortisol or temperature rhythms". Neuroscience Letters.
46. (1995). "Melatonin treatment of a non-24-hour sleep–wake cycle in a blind retarded child". Biological Psychiatry.
47. (1992). "The importance of timing in melatonin administration in a blind man". Journal of Pineal Research.
48. (1983). "Free-running activity rhythms in the rat: entrainment by melatonin". Science.
49. (2000). "Entrainment of free-running circadian rhythms by melatonin in blind people". New England Journal of Medicine.
50. (2000). "Melatonin administration can entrain the free-running circadian system of blind subjects". Journal of Endocrinology.
51. (2001). "Capturing the circadian rhythms of free-running blind people with 0.5 mg melatonin". Brain Research.
52. (2003). "The effects of low-dose 0.5-mg melatonin on the free-running circadian rhythms of blind subjects". Journal of Biological Rhythms.
53. (2002). "Low, but not high, doses of melatonin entrained a free-running blind person with a long circadian period". Chronobiology International.
54. Rajaratnam, S. M. W., Cohen, D. A., Rogers, N. L.. (2009). "Melatonin and Melatonin Analogues". Sleep Medicine Clinics.
55. "Takeda Pharmaceuticals North America, Inc". Tpna.com.
56. "Frontpage | European Medicines Agency".
57. (January 31, 2014). "FDA News Release: FDA approves Hetlioz: first treatment for non-24 hour sleep–wake disorder in blind individuals". Food and Drug Administration.
58. Rivara, S., Mor, M., Bedini, A., Spadoni, G., Tarzia, G.. (2008). "Melatonin Receptor Agonists: SAR and Application to the Treatment of Sleep–Wake Disorders". Current Topics in Medicinal Chemistry.
59. Billiard, Michel. (2003). "Sleep: Physiology, Investigations, and Medicine". Springer.
60. Carter, Louise. (March 17, 2022). "Why Does Time Go By So Fast When You Sleep?".
61. (October 1977). "Blind man living in normal society has circadian rhythms of 24.9 hours". Science.
62. (2013). "Non-24-Hour Disorder in Blind Individuals Revisited: Variability and the Influence of Environmental Time Cues". Sleep.
63. (7 July 2009). "Hypersensitivity of melatonin suppression in response to light in patients with delayed sleep phase syndrome". Chronobiology International.
64. (10 July 2017). "Sensibilité non-visuelle à la lumière et décalage du cycle éveil-sommeil". Université de Montréal.
65. (2008). "The Effects of the Mars Exploration Rovers (MER) Work Schedule Regime on Locomotor Activity Circadian Rhythms, Sleep and Fatigue". NASA Ames Research Center.
66. (1 October 2012). "Learning to live on a Mars day: fatigue countermeasures during the Phoenix Mars Lander mission.". Sleep.